Opinion|Videos|May 7, 2025
Advanced Treatment Options in Parkinson Disease
Panelists discuss how physicians typically consider advanced Parkinson disease treatments when conventional therapies fail to adequately control motor fluctuations, highlighting challenges such as adverse effects, device-related complications, and patient selection criteria.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Advanced Treatment Considerations and Challenges
Timing for Advanced Treatment Consideration:
- When standard oral medications fail to adequately control motor fluctuations
- When optimal oral therapy causes intolerable adverse effects
- When quality of life is significantly impacted despite medication optimization
- Usually 5 to 10 years into disease course
- When off time exceeds 2 hours daily despite optimization
Challenges With Current Treatment Options:
- Narrow therapeutic window of levodopa (balancing efficacy vs dyskinesias)
- Pharmacokinetic limitations of oral medications
- Gastrointestinal dysfunction affecting medication absorption
- Cognitive decline limiting complex medication regimens
- Peripheral adverse effects (orthostasis, nausea, impulse control disorders)
- Patient adherence to complex regimens
- Surgical interventions: patient selection criteria, resource limitations, expertise availability
- Cost and insurance coverage barriers for advanced therapies
Advertisement
Related to this article
The executive medical director at AbbVie discussed the FDA approval of tavapadon, the first D1/D5 dopamine agonist for Parkinson disease, including the supporting TEMPO trial data and safety considerations.
Catch up on any of the neurology headlines you may have missed in October 2026, compiled into 1 place by the NeurologyLive® team.
Here's some of what is coming soon to NeurologyLive® this week.
Newly presented biomarker and clinical findings from the phase 2b PARADIGM trial of PrimeC informed the design of the global phase 3 PARAGON trial in ALS.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the 2026 AHA/ASA Guideline for Adult Stroke Rehabilitation and Recovery!
Two-year data from the phase 2 DAZALS trial showed a lower risk of death with dazucorilant 300 mg/day vs placebo in ALS, although the study did not meet its functional primary end point.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 6, 2026.
Williams, MD, is joined by Marcus Gates, MD, and they discuss recognizing cervical nerve root and spinal cord compression, navigating treatment options, and determining when surgery may be appropriate.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
PrimeC Lowers Neuron-Derived TDP-43, Informing Phase 3 PARAGON Trial in ALS
2
ALS Agent Dazucorilant Associated With Lower 2-Year Mortality in Exploratory DAZALS Analysis
3
FDA Grants Priority Review to Huntington Disease Gene Therapy BLA, Sevasemten Misses Primary, Secondary End Points in BMD, Overviewing the 1-Year KYSA-8 Findings
4
QurAlis Reports ANQUR Interim Data for STATHMIN-2-Targeting Agent QRL-201 in ALS
5